Comparative Analysis of Myelofibrosis Treatment Outcomes with the Use of Ruxolitinib Versus Ruxolitinib with Subsequent Allogeneic Hematopoietic Stem Cell Transplantation

Aim. To comparatively analyze myelofibrosis treatment outcomes with the use of ruxolitinib versus ruxolitinib with subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT) as well as to assess the efficacy of ruxolitinib in pre- and post-transplantation periods. Materials & Metho...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Mariya Vladimirovna Barabanshchikova, E. V. Morozova, Yu. Yu. Vlasova, T. L. Gindina, A. V. Evdokimov, I. M. Barkhatov, V. V. Baikov, I. O. Ivanova, T. A. Rudakova, E. A. Bakin, I. S. Moiseev, A. D. Kulagin
Aineistotyyppi:	Artigo
Kieli:	Russo
Julkaistu:	Practical Medicine Publishing House 2021-01-01
Sarja:	Клиническая онкогематология
Aiheet:	myelofibrosis ruxolitinib allogeneic hematopoietic stem cell transplantation
Linkit:	https://bloodjournal.ru/index.php/coh/article/view/167
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!